SC2.0 More Details »
Click for More...
for gene synthesis, only 2 days and $49
Free gRNA design $199/construct
The following, free, archived webinars on antibody drug discovery-related topics are meant to address the most burning concerns in a typical antibody drug discovery campaign. In these webinars GenScript experts highlight strategies and techniques and discuss services that can streamline your antibody drug discovery efforts and help you avoid common pitfalls in your experimental designs.
Are you working on a Therapeutic Antibody project and considering the use of recombinant Antibodies (rAbs)? If yes, this webinar is for you. Monoclonal antibodies (mAbs) have emerged as the fastest growing class of therapeutics and there is a robust increase in the research and discovery of mAbs. While existing Ab discovery platforms are robust and effective, often times they need to be complemented with rAb production techniques. This webinar provides a big picture of rAb production technologies including high throughput (HTP) approaches for rAb production, within the context of therapeutic Ab projects. Case studies and GenScript rAb production services that match customer needs will also be discussed.
Are you developing antibody drugs? Have you considered generating anti-idiotype antibodies (anti-IDs)? Anti-IDs recognize the region unique to your antibody drug, the complementarity determining region (CDR), making them useful in pharmacokinetic (PK) and pharmacodynamic (PD) studies to specifically measure circulating antibody drug concentrations. They also serve as positive controls or reference standards in immune response (IR) assays. Join this interactive webinar to learn about the different types of anti-IDs and their use in PK/PD and immunogenicity assays. We will review the obstacles and solutions surrounding the generation of highly sensitive, highly specific anti-IDs with examples from vaccine and antibody drug development case studies.
Have you tried to make an antibody yet? Antibodies have become integral biochemical research tools and recently have emerged as their own class of biologic therapeutics. Antibody generation is now a requirement of both academic laboratories and pharmaceutical companies striving to stay at the forefront of their field. Although, the technology has been developing for some time, there are significant challenges that must be overcome throughout the antibody generation process. Self-tolerance, low antibody affinity, and production of required amounts of antigen with native structure are just a few such hurdles. This webinar outlines antibody generation difficulties and focuses on the corresponding solutions such as immunomodulation, GANP mice, and DNA Immunization.
Are you working on antibody drug development with a challenging target, such as membrane proteins (e.g. GPCRs and ion channels), immune checkpoint proteins and cytokines etc.? Join this interactive webinar to learn the state of the art technologies on antibody drug discovery, available platforms on the market and their intended applications, as well as strategies in handling those difficult antibody drug targets. Detailed process of DNA immunization, anti-idiotype and surrogate antibody development will be discussed in this webinar.
Interested in rapid and efficient stable cell pool/cell line development for large-scale production of your recombinant antibodies and proteins? If so, this webinar may be for you. In this session, we will review some basic information about generating a stable cell pool/cell line using the Glutamine Synthetase-based system. We will also compare the usability of Glutamine Synthetase Expression Technology system alongside the Dihydrofolate Reductase (DHFR) system for different applications. Topics such as how to efficiently screen stable pool/stable clones for increased expression, how to monitor the consistency, reliability, robustness and potency of products during scale-up will also be discussed.
Is your antibody design strategy becoming a bottleneck in achieving high levels of recombinant antibody expression? If so, this webinar may be for you. In this session we will review some antibody basics and see how sequence information correlates with its heterologous expression in mammalian cells. We will also provide suggestions on how to efficiently evaluate your antibody sequence in order to come up with the ideal cloning strategy, prior to expression testing. Topics include but are not limited to - identifying CDRs, analyzing the variable and constant regions and investigating unusual sequence features.
Are you struggling with a problematic antigen for antibody production? GenScript's innovative DNA immunization technology is a powerful tool for antibody development against membrane proteins, such as GPCRs and ion channels, as well as other hard-to-express protein antigens including toxic, unstable or insoluble proteins. DNA immunization provides an alternative approach to traditional antigen preparation as it relies on in vivo expression of target protein, which bypasses the need for labor-intensive in vitro protein production and maximizes the likelihood of producing high specificity/high affinity antibodies against structurally-intact native protein antigens. This webinar will provide an in-depth look at the GenScript DNA Immunization platform with special focus placed on the specific strategies and technologies our experienced scientists leverage to overcome the barriers to successful antibody development against challenging antigens.
Need a reliable tool for your antibody drug PK/PD or immunogenicity studies? Anti-idiotype antibodies (anti-IDs) serve as powerful tools for such studies, as they are able to differentiate antibody drug from endogenous antibodies and allow tracking of antibody drug in biological fluid. However, it has been challenging to develop highly specific and sensitive anti-IDs due to the low percentage of anti-IDs relative to other naturally-occurring antibodies in immunized animals. This webinar will take an in-depth look into the field of anti-IDs, including the obstacles and solutions surrounding the generation of highly sensitive, highly specific anti-IDs, as well as their use in vaccine development, PK/PD and immunogenicity studies.
In the past decade, drug discovery has focused on developing biologics. In particular, antibody therapeutics have been proven to be clinically effective for disease areas such as oncology and immunology. The antibody approach offers greater target specificity as well as a new way forward with previously challenging targets, such as ion channels and g-coupled protein receptors. With increased numbers of antibody drug entities entering the pipeline, antibody therapeutics will continue to dominate the drug discovery landscape. Frank Fan, GenScript's Director of Antibody and Protein Engineering will discuss the different approaches to antibody drug discovery and how these approaches can help achieve an antibody lead candidate.
Please contact us if you need immediate assistance.
Please contact us (phone: 1-877-436-7274 or email: firstname.lastname@example.org),if you need immediate assistance.